← Back to Search

Elranatamab Access for Multiple Myeloma (MagnetisMM15 Trial)

Phase 4
Recruiting
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved

Summary

This trial gives MM patients continued access to elranatamab, a drug that has helped them. It's sponsored by Pfizer.

Who is the study for?
This trial is for people with Multiple Myeloma who are benefiting from Elranatamab in ongoing Pfizer studies. They must agree to follow reproductive safety measures and cannot join if they've left the original study or have conditions that increase risk or suicidal thoughts recently.
What is being tested?
The study provides continued access to Elranatamab, a medication under investigation, for participants who were part of previous trials (Parent Studies) and are still seeing positive effects from the treatment.
What are the potential side effects?
While specific side effects of Elranatamab aren't listed here, similar treatments often cause immune reactions, fatigue, nausea, bone marrow suppression which can lead to infections or bleeding problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ElranatamabExperimental Treatment1 Intervention
Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Elranatamab
2023
N/A
~1030

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,655 Previous Clinical Trials
17,746,186 Total Patients Enrolled
41 Trials studying Multiple Myeloma
10,586 Patients Enrolled for Multiple Myeloma
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,542 Previous Clinical Trials
14,917,362 Total Patients Enrolled
29 Trials studying Multiple Myeloma
5,791 Patients Enrolled for Multiple Myeloma
~48 spots leftby Feb 2031
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top